• What does a low recurrence score (0-25) indicate?

A low score indicates a low risk of cancer return, and the benefit of chemotherapy is usually minimal in these cases.

• What does a high recurrence score (26-100) indicate?

A high score indicates a higher risk of cancer return, meaning chemotherapy is likely to be beneficial for the patient.

Book Oncotype DX Test in Saudi Arabia | Lahalak Medical Platform

Lahalak Medical PlatformDifferentiate Care

Medical notice: this information is for education and service understanding. It is not a diagnosis or a recommendation for an unnecessary procedure.

About this service

A genomic test analyzing 21 genes in breast cancer tissue to calculate a recurrence score. It predicts cancer return risk and chemotherapy effectiveness, enabling personalized and precise treatment plans.

Purpose of the Assay

Determine the likelihood of breast cancer recurrence within 10 years.
Predict whether chemotherapy will be beneficial for the patient.
Enable a personalized treatment plan based on the tumor's genetic profile.

Target Groups

Patients diagnosed with early-stage breast cancer (Stage I or II).
Hormone receptor-positive (HR+) tumor cases.
HER2-negative breast cancer cases.

Understanding the Results

Low Recurrence Score (0-25): Low risk of return; chemotherapy benefit is usually minimal.
High Recurrence Score (26-100): Higher risk of return; chemotherapy is likely to be beneficial.

What is included?

✓21-gene expression analysis
✓Recurrence Score report
✓Chemotherapy benefit assessment

Conditions and notices

Fasting is not required
Requires a preserved tissue sample from the tumor (biopsy or surgery)
Typically for patients with early-stage breast cancer

Frequently Asked Questions

Short answers to the FAQs published with this service.

• What is the Oncotype DX Breast Cancer Assay?

It is a genomic test that analyzes 21 genes in breast cancer tissue to calculate a recurrence score, helping to create a personalized treatment plan.

• Is fasting required for this breast cancer test?

No, fasting is not required for this genomic assay.

• What is the primary purpose of this assay?

The test is used to determine the likelihood of breast cancer returning within 10 years and to predict if the patient will benefit from chemotherapy.

• Who is the target group for Oncotype DX?

Service resources and references

References and additional resources

Reference material and files associated with this service when available.

Scientific references

American Society of Clinical Oncology (ASCO)
National Comprehensive Cancer Network (NCCN)

Precision Treatment for Breast Cancer

About this service

Purpose of the Assay

Target Groups

Understanding the Results

What is included?

Conditions and notices

Frequently Asked Questions

References and additional resources

Scientific references

Choose a provider and branch

Let us help you

Didn’t find the service?

Services you might also like

Discover Your Genetic Cancer Risk

Fanconi Anemia Genetic Screening

Discover Genetic Causes of HSP

Leukemia Gene Fusion Test

Your opinion matters

Was this content helpful?

Have a note?